Name of study:
Gates MRI- COD-01-T01-01 Amendment 1
Targeted disease:
COVID-19
Purpose of study:
A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban(Xarelto®) for high risk people with mild COVID-19.
Is this a pre- or post- market study?:
Pre-Market Study (151445)
Is the study of a controlled or observational design?
Controlled
What is the funding source?:
Sponsor funded- Bill & Melinda Gates Medical Research Institute
Where is the study being conducted?
Multi-Center Trial
Lead Institution:
Allergy & Asthma Medical Group and Research Center A P.C
City and State:
San Diego, California
When the study is being conducted:
Start Date: 9/1/2020
End date: Unknown
What website should a person use to register for the study?
www.allergyandasthma.com
Who should a person contact to register for the study?
Name: Silvia Cedillo
Phone: 858.268.2368 ext 130
Email: [email protected]
Who is sponsoring this study?
Bill & Melinda Gates Medical Research Institute (Gates MRI)
What is the identifier for this study on ClinicalTrials.gov?
NCT04504032
Page last updated: February 23, 2021
